Voyager Therapeutics (VYGR) Change in Accured Expenses (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Change in Accured Expenses data on file, last reported at -$5.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses changed 0.16% year-over-year to -$5.1 million; the trailing twelve-month figure through Mar 2026 stood at -$2.5 million (down 263.39% YoY), and the FY2025 full-year result was -$2.5 million, up 5.73% from the prior year.
• Change in Accured Expenses slipped to -$5.1 million in Q1 2026, from -$3.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $5.8 million in Q4 2023 to a low of -$9.3 million in Q1 2024.
• A 5-year average of -$259941.2 and a median of $1.2 million in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses jumped 1065.84% in 2022 and tumbled 7527.05% in 2024, its largest moves.
• Tracing VYGR's Change in Accured Expenses over 5 years: stood at -$4.7 million in 2022, then soared by 223.21% to $5.8 million in 2023, then slumped by 52.71% to $2.7 million in 2024, then tumbled by 216.71% to -$3.2 million in 2025, then sank by 60.94% to -$5.1 million in 2026.
• Business Quant data shows VYGR's Change in Accured Expenses at -$5.1 million in Q1 2026, -$3.2 million in Q4 2025, and $2.8 million in Q3 2025.